Related Experiment Video
Updated: Jun 7, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Diabetes, metformin and lactic acidosis
1Wrexham Academic Unit, Centre for Endocrinology and Diabetes, Wales College of Medicine, Cardiff University, Wrexham, UK.
Clinical Endocrinology
|November 3, 2010
Summary
Metformin does not increase the risk of lactic acidosis (LA). Diabetes and acute illnesses are the primary risk factors for LA, suggesting current metformin guidelines may overstate its role.
Area of Science:
- Clinical Medicine
- Pharmacology
- Nephrology
Background:
- Metformin is widely suspected of causing lactic acidosis (LA).
- Emerging evidence questions a direct causal link between metformin and LA.
- This study investigates the relationship between metformin use and LA incidence.
Purpose of the Study:
- To assess the incidence of lactic acidosis (LA) in patients taking metformin.
- To identify factors contributing to LA beyond metformin therapy.
- To re-evaluate current clinical guidelines on metformin and LA prevention.
Main Methods:
- Retrospective analysis of all LA cases identified via laboratory lactate measurements.
- Comparison of LA incidence in diabetic versus non-diabetic patients.
- Assessment of metformin use and other potential contributing factors in LA development.
Main Results:
- Lactic acidosis (LA) incidence was higher in diabetic patients compared to non-diabetics.
- No increased incidence of LA was observed in patients taking metformin.
- Acute cardiorespiratory illness, renal impairment, and sepsis were identified as primary LA precipitants.
Conclusions:
- Diabetes, not metformin, is the primary risk factor for lactic acidosis (LA).
- LA is strongly associated with acute illnesses, especially in diabetic patients.
- Current guidelines may overestimate metformin's role in LA development.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:25Diabetic Ketoacidosis l: Introduction
DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
01:22Diabetic Ketoacidosis ll: Pathophysiology
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
01:22Complications of Diabetes Mellitus
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...